Compare · BSX vs CARL
BSX vs CARL
Side-by-side comparison of Boston Scientific Corporation (BSX) and Carlsmed Inc. (CARL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and CARL operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $61.87B, about 143.7x CARL ($430.6M).
- Over the past year, BSX is down 58.3% and CARL is up 15.5% - CARL leads by 73.9 points.
- BSX has been more active in the news (10 items in the past 4 weeks vs 4 for CARL).
- BSX has more recent analyst coverage (25 ratings vs 6 for CARL).
- Company
- Boston Scientific Corporation
- Carlsmed Inc.
- Price
- $41.97-1.66%
- $14.96-4.90%
- Market cap
- $61.87B
- $430.6M
- 1M return
- -2.96%
- +8.52%
- 1Y return
- -58.34%
- +15.52%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 10
- 4
- Recent ratings
- 25
- 6
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest BSX
- Boston Scientific downgraded by TD Cowen with a new price target
- Penumbra, Inc. Reports Third Quarter 2026 Financial Results
- Boston Scientific downgraded by Oppenheimer
- Boston Scientific downgraded by Analyst with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- Boston Scientific announces results for third quarter 2026
- Boston Scientific to participate in Stifel's 2026 Healthcare Conference
- Barclays initiated coverage on Boston Scientific with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
Latest CARL
- Carlsmed, Inc. to Report Third Quarter 2026 Financial Results on November 10, 2026
- SEC Form 144 filed by Carlsmed Inc.
- Carlsmed Launches aprevo® Lumbar Bi-lateral Posterior System
- SEC Form 4 filed by Carlsmed Inc.
- Carlsmed, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Chief Operating Officer Bertolini Jeffrey sold $3,400 worth of shares (243 units at $13.99) as part of a pre-agreed trading plan and exercised 243 shares at a strike of $2.23 (SEC Form 4)
- SEC Form S-8 filed by Carlsmed Inc.
- Carlsmed Appoints Tony Jarc as Chief Product and AI Officer
- New insider Kamocsay Jennifer claimed ownership of 56,222 shares (SEC Form 3)
- CFO, Treasurer Heppenstall Richard was granted 89,286 shares (SEC Form 4)